Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.

You may also be interested in...



Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif

With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.

Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif

With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.

Antegren Brand Rejected Due To Possible Confusion With Ativan, Integrilin

Elan and Biogen Idec agreed to change the name of the multiple sclerosis monoclonal antibody natalizumab from Antegren to Tysabri after FDA expressed concern over potential drug name mix-ups

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel